These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26679394)

  • 41. A comparative analysis of heterogeneity in commercially available recombinant factor VIII products.
    Baunsgaard D; Nielsen AD; Nielsen PF; Henriksen A; Kristensen AK; Bagger HW; Ezban M
    Haemophilia; 2018 Nov; 24(6):880-887. PubMed ID: 29726070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A.
    Napolitano M; Nøhr AM
    Drugs R D; 2019 Dec; 19(4):381-390. PubMed ID: 31782067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
    Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
    Benson G; Morton T; Thomas H; Lee XY
    Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
    Manco-Johnson MJ; Kempton CL; Reding MT; Lissitchkov T; Goranov S; Gercheva L; Rusen L; Ghinea M; Uscatescu V; Rescia V; Hong W
    J Thromb Haemost; 2013 Jun; 11(6):1119-27. PubMed ID: 23528101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Susoctocog Alfa: A Review in Acquired Haemophilia A.
    Burness CB; Scott LJ
    Drugs; 2016 May; 76(7):815-21. PubMed ID: 27098420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.
    Lentz SR; Kavakli K; Klamroth R; Misgav M; Nagao A; Tosetto A; Jørgensen PJ; Zak M; Nemes L
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12674. PubMed ID: 35308099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L; Pollmann H; Becker T
    Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In silico and in vitro immunogenicity assessment of B-domain-modified recombinant factor VIII molecules.
    Bartholdy C; Reedtz-Runge SL; Wang J; Hjerrild Zeuthen L; Gruhler A; Gudme CN; Lamberth K
    Haemophilia; 2018 Sep; 24(5):e354-e362. PubMed ID: 30024643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Octocog alfa, plasma/albumin-free method.
    McCormack PL; Plosker GL
    Drugs; 2005; 65(18):2613-20, discussion 21-2. PubMed ID: 16392876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
    Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
    Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
    Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
    Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.